Update on screening for prostate cancer with prostate-specific antigen

Area of Science:

• Urology
• Oncology
• Diagnostic Medicine

Background:

• Serum prostate-specific antigen (PSA) and digital rectal examination (DRE) are recommended for opportunistic prostate cancer screening in informed patients with life expectancy >10 years.
• A major limitation of PSA is its poor specificity, leading to potential overdiagnosis and overtreatment.
• The effectiveness of population-wide (mass) screening for reducing prostate cancer mortality and impacting quality of life is still unclear.

Purpose of the Study:

• To review current recommendations and emerging strategies for prostate cancer screening using PSA.
• To discuss methods for improving the diagnostic accuracy of PSA.
• To highlight the ongoing research into the benefits and drawbacks of population-based prostate cancer screening.

Main Methods:

• Review of clinical guidelines and scientific literature on PSA and DRE for prostate cancer screening.
• Discussion of advanced PSA-based diagnostic concepts, including free/total PSA ratio and PSA doubling time.
• Consideration of evidence from ongoing national and international prospective trials on mass screening.

Main Results:

• PSA/DRE are standard for opportunistic screening but lack specificity.
• Free/total PSA ratio and PSA doubling time show promise for enhancing PSA diagnostic performance.
• Results from large-scale population screening trials are pending.

Conclusions:

• PSA/DRE remain key tools for informed, opportunistic prostate cancer screening.
• Further research and validated methods are needed to improve specificity and clarify the role of mass screening.
• Ongoing trials will provide crucial data on mortality reduction and quality of life in screened populations.